- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02193828
Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules
A Phase 2a, Double-blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Effectiveness of AA4500 in the Treatment of Dupuytren's Disease Nodules
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 13 sites in the United States and Australia, approximately 90 study subjects.
After all pre-injection procedures are completed on day 1, eligible men and women will be randomized in a 1:1:1 ratio to dose group and then in a 4:1 ratio to treatment group. Study drug will be administered into a palmar nodule located on the selected hand.
AA4500 (collagenase clostridium histolyticum) 3 doses (low, medium, and high) after reconstitution with sterile diluent (0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride). Each dose of study drug will be injected into the nodule. The injection will be administered in 3 different volumes according to randomization.
Placebo after reconstitution with sterile diluent (0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride). Each dose of study drug will be injected into the nodule. The injection will be administered in 3 different volumes according to randomization.
Follow up visits for the evaluation of safety and efficacy will be required for all subjects on days 8, 29, and 57.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia, 4000
- Brisbane Hand & Upper Limb Clinic
-
Kippa Ring, Queensland, Australia, 4021
- Houston Medical
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85712
- Tucson Orthopaedic Institute
-
-
California
-
Encinitas, California, United States, 92024
- CORE Orthopaedic Medical Center
-
Greenbrae, California, United States, 94904
- Marin Endocrine Care & Research, Inc.
-
Murrieta, California, United States, 92563
- Brigid Freyne, MD, Inc.
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Indiana Hand to Shoulder Center
-
-
New York
-
Stony Brook, New York, United States, 11794
- State University of New York
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- OrthoCarolina Research Institute, Inc.
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73109
- Orthopedic and Reconstructive Center
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States, 16602
- Blair Orthopedic Associates, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide a signed and dated informed consent
- Be a man or woman ≥ 18 years of age
Have a diagnosis of Dupuytren's disease AND have at least one palmar nodule on the selected hand that is:
- Palpable
- Measures between 0.5 cm and 2.0 cm in length and between 0.5 cm and 2.0 cm in width using hand-held calipers n
- Not directly associated with a Dupuytren's cord
- Have a negative urine pregnancy test at screening and before injection of study drug and be using a highly effective (ie, < 1% failure rate) contraception method as judged by the investigator (eg, abstinence, intrauterine device [IUD], hormonal [estrogen/progestin] contraceptives, or barrier control) for at least one menstrual cycle prior to study enrollment and for the duration of the study or be surgically sterile (if female of childbearing potential); or be a postmenopausal female (no menses for at least 1 year or hysterectomy)
- Be able to comply with the study visit schedule as specified in the protocol
Exclusion Criteria:
- Received steroid injections (eg, tri-amcinolone acetonide) on the selected nodule within 3 months before administration of study drug
- Has a chronic muscular, neurological, or neuromuscular disorder that affects the hands
- Has a known systemic allergy to collagenase or any other excipient of AA4500
- Has received any collagenase treatments (eg, Santyl® ointment and/or XIAFLEX®/XIAPEX®) within 30 days before injection of study drug in the hand selected for treatment
- Is currently receiving or plans to receive anticoagulant medication or has received anticoagulant medication (except for ≤ 150 mg aspirin daily) within 7 days before injection of study drug
- Has a known recent history of stroke, bleeding, or other medical condition, which in the investigator's opinion would make the subject unsuitable for enrollment in the study
- Received an investigational drug within 30 days before injection of study drug
- Is pregnant or intends on becoming pregnant during the study or is breastfeeding a child
- Has any clinically significant medical history or condition(s), including conditions that affect the hands, that would, in the opinion of the investigator, substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives of the study
- Had surgery on the selected hand within 3 months before the screening visit
- Has jewelry on the hand to be treated that cannot be removed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AA4500 0.25 mg
Collagenase clostridium histolyticum, single 0.25 mg injection
|
Single injection into nodule
Other Names:
|
EXPERIMENTAL: AA4500 0.40 mg
Collagenase clostridium histolyticum, single 0.40 mg injection
|
Single injection into nodule
Other Names:
|
EXPERIMENTAL: AA4500 0.60 mg
Collagenase clostridium histolyticum, single 0.60 mg injection
|
Single injection into nodule
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Placebo, single 0.25 mg, 0.40 mg, or 0.60 mg injection
|
Single injection into nodule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Caliper Measurements
Time Frame: Baseline, Day 57
|
Percent change from baseline in surface area and volume of the treated nodule was determined from hand-held caliper measurements of the length and width of the nodule.
Percent change = 100*(Day 57 area [or volume] - baseline area [or volume])/baseline area [or volume].
A negative value represents the improvement from baseline (decreased size) while a positive value represents worsening.
|
Baseline, Day 57
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Ultrasound
Time Frame: Baseline, Day 57
|
Percent change from baseline in surface area and volume of the treated nodule was determined from ultrasound measurements of the length, width, and depth of the nodule.
Percent change = 100*(Day 57 area [or volume] - baseline area [or volume])/baseline area [or volume].
A negative value represents the improvement from baseline (decreased size) while a positive value represents worsening.
|
Baseline, Day 57
|
Change From Baseline in Consistency of the Treated Nodules at Day 57
Time Frame: Baseline, Day 57
|
Investigators determined the consistency of the nodule through palpitation using a 5-point scale: 5 = hard (solid), 4 = firm throughout, 3 = moderate firmness, 2 = soft, and 1 = non-palpable.
The change scores could range from +4 (greatest worsening in consistency) to -4 (greatest improvement in consistency); a negative change from baseline value reflects improvement from baseline (softening) while a positive value reflects worsening.
|
Baseline, Day 57
|
Percent Change From Baseline in Hardness of the Treated Nodule at Day 57
Time Frame: Baseline, Day 57
|
A durometer was used to assess nodule hardness on a scale of 0 (soft) to 100 (hard).
Percent change = 100*(Day 57 hardness - baseline hardness)/baseline hardness.
A negative value represents the improvement from baseline (softening) while a positive value represents worsening.
|
Baseline, Day 57
|
Change From Baseline in Nodular Pain of the Treated Nodule at Day 57
Time Frame: Baseline, Day 57
|
After the nodule was squeezed using a dynamometer, subjects were asked to rate the amount of pain they felt on an 11-point visual analog scale (VAS) from 0 (no pain or discomfort) to 10 (extreme pain or discomfort).
A negative change from baseline value reflects improvement from baseline (less pain) while a positive value reflects worsening.
|
Baseline, Day 57
|
Investigator Global Assessment of Improvement With Treatment
Time Frame: Day 57
|
Investigators were asked to determine the degree of improvement in the subject's treated nodule compared with screening on a 7-point scale: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
|
Day 57
|
Subject Satisfaction With Treatment
Time Frame: Day 57
|
Subjects were asked to rate their satisfaction with treatment on a 5-point scale: 1 = very satisfied, 2 = quite satisfied, 3 = neither satisfied nor dissatisfied, 4 = quite dissatisfied, and 5 = very dissatisfied.
|
Day 57
|
Composite Responder Analysis
Time Frame: Day 57
|
A composite responder is a subject who had an improved assessment [values of 1 (very much improved), 2 (much improved), or 3 (minimally improved)] on the investigator global assessment and had a satisfied assessment [values of 1 (very satisfied) or 2 (quite satisfied)] on the subject assessment.
|
Day 57
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Veronica Urdaneta, MD MPH, Endo Pharmaceuticals
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AUX-CC-750
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dupuytren's Disease
-
University of MinnesotaRecruitingDupuytren Contracture | Dupuytren Disease of Finger | Dupuytren's Disease | Dupuytren Disease of Palm and Finger | Dupuytrens Contracture of Both Hands | Dupuytren's Disease of Palm of Right Hand | Dupuytren's Disease of Palm of Left Hand | Dupuytren Contracture of Right Palm | Dupuytren Contracture... and other conditionsUnited States
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseUnited States
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseUnited States
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseAustralia
-
University of CalgaryUnknownDupuytren Contracture | Dupuytren's Disease of FingerCanada
-
Regionshospitalet SilkeborgRecruitingNeoplasms | Neoplasms, Connective and Soft Tissue | Neoplasms by Histologic Type | Joint Diseases | Musculoskeletal Diseases | Connective Tissue Diseases | Neoplasms, Connective Tissue | Fibroma | Contracture | Dupuytren Contracture | Dupuytren's Disease | Neoplasm, Fibrous TissueDenmark
-
Uppsala UniversityRecruitingDupuytren Contracture | Dupuytren's DiseaseSweden
-
Hospital for Special Surgery, New YorkAuxilium Pharmaceuticals, Inc.CompletedDupuytren's DiseaseUnited States
-
Indiana Hand to Shoulder CenterStony Brook UniversityTerminatedDupuytren's DiseaseUnited States
-
Foundation for Orthopaedic Research and EducationEndoPharmceuticalsActive, not recruitingDupuytren Contracture | Dupuytren's DiseaseUnited States
Clinical Trials on Collagenase clostridium histolyticum
-
Stony Brook UniversityCompletedAdhesion of Flexor Tendon of HandUnited States
-
Endo PharmaceuticalsCompletedEdematous SkinUnited States
-
Zachary GerutAdvance Biofactures CorporationCompleted
-
Endo PharmaceuticalsCompleted
-
Endo PharmaceuticalsCompletedLaxity; Skin | Cellulite | Edematous Fibrosclerotic PanniculopathyUnited States
-
Advance Biofactures CorporationCompletedLeiomyoma | Fibroids, UterineUnited States
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseAustralia
-
Endo PharmaceuticalsCompletedCellulite | Edematous Fibrosclerotic PanniculopathyUnited States
-
Endo PharmaceuticalsCompletedCellulite | Edematous Fibrosclerotic PanniculopathyUnited States
-
Endo PharmaceuticalsCompletedEdematous Fibrosclerotic PanniculopathyUnited States